Vaccinex Inc. (VCNX)
0.60
-0.16 (-21.05%)
At close: Apr 03, 2025, 12:23 PM
0.60
0.00%
After-hours: Apr 03, 2025, 12:23 PM EDT
-21.05% (1D)
| Bid | 0.5 |
| Market Cap | 1.61M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | 7.42 |
| PE Ratio (ttm) | 0.08 |
| Forward PE | -8.5 |
| Analyst | n/a |
| Ask | 0.7 |
| Volume | 1 |
| Avg. Volume (20D) | 4,176 |
| Open | 0.76 |
| Previous Close | 0.76 |
| Day's Range | 0.60 - 0.76 |
| 52-Week Range | 0.28 - 8.90 |
| Beta | 1.35 |
About VCNX
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatmen...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 9, 2018
Employees 37
Stock Exchange OTC
Ticker Symbol VCNX
Website https://www.vaccinex.com
3 months ago
-61.37%
Vaccinex shares are trading lower after the compan...
Unlock content with
Pro Subscription
5 months ago
-30.77%
Vaccinex shares are trading lower. The company provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer's disease.
